TAT-Gap19 TFA |
Catalog No.GC62257 |
TAT-Gap19 TFA, un péptido mimético de Cx, es un inhibidor especÍfico del hemicanal de conexina 43 (Cx43 HC).
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
TAT-Gap19 TFA, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 TFA does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 TFA traverses the blood-brain barrier and alleviate liver fibrosis in mice[1][2][3].
A single injection of TAT-Gap19 TFA (i.v. via the tail vein; 55 mg/kg) produces significant immune signal in the brain 24 h later in 4 months old C57Bl6 male mice[1]. TAT-Gap19 TFA (1 mg/kg/day; an osmotic pump implanted in the peritoneal cavity; Two weeks) shows significantly decreased collagen deposition, as well as lowed amounts of α-SMA-positive cells area in mice subjected to treatment with 100-200 mg thioacetamide (TAA)/kg body weight for eight weeks[2].
[1]. VerÓnica Abudara, et al. The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes. Front Cell Neurosci. 2014 Oct 21;8:306.
[2]. Sara Crespo Yanguas, et al. TAT-Gap19 and Carbenoxolone Alleviate Liver Fibrosis in Mice. Int J Mol Sci. 2018 Mar 12;19(3):817.
[3]. Laura Walrave, et al. Inhibition of astroglial connexin43 hemichannels with TAT-Gap19 exerts anticonvulsant effects in rodents. Glia. 2018 Aug;66(8):1788-1804.
Average Rating: 5
(Based on Reviews and 23 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *